Phacoemulsification surgery for Cataract

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alcon Investigator 2187, Mount Pleasant, SC
Cataract+1 More
Phacoemulsification surgery - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The primary purpose of this study is to compare the Clareon/Clareon Toric Intraocular Lenses (IOLs) to the Eyhance/Eyhance Toric IOLs in binocular Best Corrected Distance Visual Acuity (BCDVA) at 3 months postoperative.

Eligible Conditions

  • Cataract
  • Aphakia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Month 3 postoperative visit

Month 3 postoperative visit
Mean binocular best-corrected distance visual acuity (BCDVA) at 4 meters

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Eyhance/Eyhance Toric
1 of 2
Clareon/Clareon Toric
1 of 2
Active Control
Experimental Treatment

185 Total Participants · 2 Treatment Groups

Primary Treatment: Phacoemulsification surgery · No Placebo Group · N/A

Clareon/Clareon ToricExperimental Group · 3 Interventions: Clareon Toric IOL, Phacoemulsification surgery, Clareon IOL · Intervention Types: Device, Procedure, Device
Eyhance/Eyhance ToricActiveComparator Group · 3 Interventions: Eyhance Toric IOL, Eyhance IOL, Phacoemulsification surgery · Intervention Types: Device, Device, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phacoemulsification surgery
2013
N/A
~60

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 3 postoperative visit
Closest Location: Alcon Investigator 2187 · Mount Pleasant, SC
Photo of south carolina 1Photo of south carolina 2Photo of south carolina 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Cataract
0 CompletedClinical Trials

Who is running the clinical trial?

Alcon ResearchLead Sponsor
651 Previous Clinical Trials
115,811 Total Patients Enrolled
109 Trials studying Cataract
20,594 Patients Enrolled for Cataract
Clinical Trial Lead, CDMA SurgicalStudy DirectorAlcon Research, LLC

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.